

Special Issue

Advances in Blood-Based Screening for Cancer

Message from the Guest Editors

In medicine, tissue is the issue; hence the novel technique of liquid biopsy (LB) has become highly relevant. LB consists of detecting proteins, RNA, DNA, and nanovesicles such as exosomes in the bloodstream and other body effluents and can potentially facilitate the diagnosis and monitoring of cancer and other diseases. LB can detect not only cell-free DNA (cfDNA) but also mutations, methylations, and copy number variants. Although LB is not routinely used, the ongoing research highlights the potential clinical applications of LBs and increases its popularity. This Special Issue welcomes basic and clinical research that highlights and discusses different approaches used in non-invasive monitoring allowing for tumor diagnosis, evaluation of the response to treatment, tumor progression, recurrence, and prognosis. It is also of interest to receive contributions addressing new developments of ctDNA detection methods and proposing combination strategies employing multianalyte approaches, in addition to discussing specificity, sensitivity, and reproducibility of this new biopsy technology.

Guest Editors

Dr. Shiran Shapira

The Integrated Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Prof. Dr. Nadir Arber

The Integrated Cancer Prevention Center, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel

Deadline for manuscript submissions

closed (23 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/136069

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)